Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of AX 250 in MPS IIIB
NCT03784287Phase 2Unknown
- Sponsor
- Allievex
- Start
- Feb 2018
- Primary completion
- Jan 2025
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of tralesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Allievex. Primary endpoints: Number of participants with abnormal clinical laboratory values and/or Adverse Events related to the treatment at 240 weeks and Developmental Quotient at 240 weeks. Status: unknown.
02
Drugs
tralesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT03784287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784287.